Comparative Pharmacology
Head-to-head clinical analysis: TAMBOCOR versus TIKOSYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TAMBOCOR versus TIKOSYN.
TAMBOCOR vs TIKOSYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ic antiarrhythmic agent; blocks sodium channels, slowing conduction velocity and prolonging refractoriness in cardiac tissues.
Selective class III antiarrhythmic agent; blocks cardiac potassium channels (IKr), prolonging action potential duration and effective refractory period.
For atrial fibrillation/flutter: 50 mg orally every 12 hours; may increase by 50 mg every 4 days up to 300 mg/day. For life-threatening ventricular arrhythmias: 100 mg orally every 12 hours; increase by 50 mg every 4 days up to 400 mg/day.
500 mcg orally twice daily for atrial fibrillation/flutter conversion and maintenance of sinus rhythm.
None Documented
None Documented
Terminal elimination half-life: 12–27 hours (mean 20 hours); prolonged to 58 hours in heart failure or renal impairment (CrCl < 35 mL/min).
10 hours (terminal) in patients with normal renal function; prolonged to up to 42 hours in severe renal impairment; clinically relevant for dosing interval adjustment.
Renal: 85% (30% unchanged, 55% as inactive metabolites); Fecal: 5%; Biliary: negligible.
Renal: 80% as unchanged drug; biliary/fecal: 20% (metabolites and minor parent drug).
Category C
Category C
Antiarrhythmic Agent
Antiarrhythmic Agent